Amarna Therapeutics

Amarna Therapeutics company information, Employees & Contact Information

Amarna Therapeutics is a privately held, pre-clinical biotech company developing transformative, potentially curative gene therapies for a range of both rare and prevalent diseases. The company is pioneering the development of gene therapies based on simian virus 40 (SV40), a macaque polyoma virus to which humans are immunologically naïve. Amarna has created a proprietary production cell line (SuperVero™) that, for the first time, makes it possible to produce SV40-derived vectors suitable for therapeutic use. Combining SuperVero™ with its genetically engineered SVec viral vector, the company’s fully-integrated gene therapy platform is truly unique in its intrinsic capability to deliver transgenes without eliciting immune responses to the vector nor to the transgene product. Leveraging this ‘natural’ non-immunogenicity feature of its gene delivery system in humans, Amarna is developing a broad pipeline of safe, effective and durable gene therapies focused on genetic disorders, autoimmune diseases and chronic inflammation. Founded in 2008, Amarna’s head office is based in Leiden Bio Science Park, the Netherlands, with a research subsidiary located in Seville, Spain.

Company Details

Employees
17
Founded
-
Address
J.h. Oortweg 21, Leiden,2333ch,netherlands
Email
in****@****ics.com
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
Leiden
Looking for a particular Amarna Therapeutics employee's phone or email?

Amarna Therapeutics Questions

News

Amarna Therapeutics and NorthX Biologics Finalize Agreement to Advance Nimvec™ AM510 Gene Therapy Toward Clinical Trials for Type 1 Diabetes - GlobeNewswire

Amarna Therapeutics and NorthX Biologics Finalize Agreement to Advance Nimvec™ AM510 Gene Therapy Toward Clinical Trials for Type 1 Diabetes GlobeNewswire

Amarna Therapeutics Partners with NorthX Biologics to Advance Nimvec™ AM510 Gene Therapy Development - GlobeNewswire

Amarna Therapeutics Partners with NorthX Biologics to Advance Nimvec™ AM510 Gene Therapy Development GlobeNewswire

Dutch Amarna Therapeutics Announces the Appointment of Steen Klysner as Chief Executive Officer - PR Newswire

Dutch Amarna Therapeutics Announces the Appointment of Steen Klysner as Chief Executive Officer PR Newswire

New Chief Business Officer for Amarna Therapeutics - European Biotechnology Magazine

New Chief Business Officer for Amarna Therapeutics European Biotechnology Magazine

How Simian Virus 40 Hijacks the Intracellular Protein Trafficking Pathway to Its Own Benefit … and Ours - Frontiers

How Simian Virus 40 Hijacks the Intracellular Protein Trafficking Pathway to Its Own Benefit … and Ours Frontiers

Amarna Therapeutics announces formation of Scientific Advisory Board to support advancement of groundbreaking Nimvec™ AM510 gene therapy against Type 1 Diabetes - GlobeNewswire

Amarna Therapeutics announces formation of Scientific Advisory Board to support advancement of groundbreaking Nimvec™ AM510 gene therapy against Type 1 Diabetes GlobeNewswire

Top Amarna Therapeutics Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant